Tocqueville Asset Management L.P. lifted its holdings in Tandem Diabetes Care Inc (NASDAQ:TNDM) by 103.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 8,250 shares of the medical device company’s stock after buying an additional 4,200 shares during the period. Tocqueville Asset Management L.P.’s holdings in Tandem Diabetes Care were worth $487,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of TNDM. FMR LLC increased its holdings in shares of Tandem Diabetes Care by 248.9% in the 1st quarter. FMR LLC now owns 705,789 shares of the medical device company’s stock worth $44,818,000 after buying an additional 503,482 shares during the last quarter. Chicago Capital LLC bought a new stake in shares of Tandem Diabetes Care in the 2nd quarter worth about $14,641,000. Nisa Investment Advisors LLC increased its holdings in shares of Tandem Diabetes Care by 53.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after buying an additional 160 shares during the last quarter. Polianta Ltd bought a new stake in shares of Tandem Diabetes Care in the 2nd quarter worth about $1,071,000. Finally, Foundry Partners LLC bought a new stake in shares of Tandem Diabetes Care in the 2nd quarter worth about $1,860,000. Hedge funds and other institutional investors own 80.49% of the company’s stock.

A number of research firms have recently weighed in on TNDM. ValuEngine upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Guggenheim began coverage on shares of Tandem Diabetes Care in a report on Thursday, October 17th. They issued a “buy” rating and a $76.00 target price on the stock. BidaskClub downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Robert W. Baird cut their price target on shares of Tandem Diabetes Care from $81.00 to $71.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, UBS Group upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating and set a $75.00 price target on the stock in a report on Friday, October 4th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $76.54.

In related news, EVP Brian B. Hansen sold 15,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $62.97, for a total transaction of $944,550.00. Following the transaction, the executive vice president now directly owns 17,991 shares in the company, valued at approximately $1,132,893.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward L. Cahill sold 1,417 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $63.03, for a total transaction of $89,313.51. Following the transaction, the director now owns 5,399 shares in the company, valued at $340,298.97. The disclosure for this sale can be found here. Insiders have sold a total of 458,221 shares of company stock worth $32,039,235 over the last quarter. 6.90% of the stock is currently owned by insiders.

Shares of NASDAQ:TNDM opened at $59.21 on Friday. The company has a market capitalization of $3.42 billion, a price-to-earnings ratio of -23.22 and a beta of 0.16. Tandem Diabetes Care Inc has a 12 month low of $26.40 and a 12 month high of $74.81. The firm’s 50-day moving average is $60.50 and its 200 day moving average is $63.78. The company has a current ratio of 2.46, a quick ratio of 2.21 and a debt-to-equity ratio of 0.09.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

See Also: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care Inc (NASDAQ:TNDM).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.